On Tuesday, argenx ADR earned an upgrade to its Relative Strength (RS) Rating, from 80 to 84.
Hone Your Stock-Picking Skills By Focusing On These Factors
IBD's proprietary rating measures share price movement with a 1 (worst) to 99 (best) score. The score shows how a stock's price movement over the trailing 52 weeks holds up against all the other stocks in our database.
Decades of market research shows that the best stocks typically have an RS Rating north of 80 in the early stages of their moves.
argenx ADR is building a consolidation with a 678.21 buy point. See if it can break out in heavy trading.
The company posted 0% earnings growth last quarter, while sales growth came in at 96%.
The company holds the No. 12 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, Catalyst Pharmaceuticals and ADMA Biologics are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
